• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Ark Invest’s Steady Buying Reframing the Long-Term Product Expansion Story At 10x Genomics (TXG)?

    Simply Wall St·03/29/2026 00:22:33
    Listen to the news
    • Cathie Wood’s Ark Invest recently added to its position in 10x Genomics over four consecutive trading sessions, highlighting renewed institutional interest in the life sciences tools maker and its single-cell Chromium platform.
    • This persistent buying streak by a high-profile investor brings additional attention to 10x Genomics’ role in advanced genomics workflows, potentially influencing how other market participants view its long-term demand outlook.
    • We’ll now examine how Cathie Wood’s ongoing accumulation of shares interacts with 10x Genomics’ existing investment narrative around product expansion.

    Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

    10x Genomics Investment Narrative Recap

    To own 10x Genomics, you need to believe single cell and spatial genomics will remain central to research workflows and that the company can translate its platforms into durable consumables demand despite ongoing losses. Cathie Wood’s four day buying streak adds visibility but does not materially change the near term catalyst, which still hinges on successful uptake of newer, lower cost consumables, nor the key risk around pressured research budgets and cautious capital spending.

    Among recent developments, the Q4 2025 results stand out alongside fresh 2026 revenue guidance of US$600 million to US$625 million, showing management’s current expectations for the business against a backdrop of uneven quarterly performance. In the context of Ark’s accumulation, these numbers frame how much room there is for sentiment to shift if adoption of platforms like Chromium Flex and Xenium either outperforms or lags those revenue targets.

    Yet while Ark’s buying draws attention, investors should also be aware of the ongoing strain from research funding uncertainty and its potential to...

    Read the full narrative on 10x Genomics (it's free!)

    10x Genomics' narrative projects $709.8 million revenue and $110.2 million earnings by 2029.

    Uncover how 10x Genomics' forecasts yield a $20.14 fair value, a 3% upside to its current price.

    Exploring Other Perspectives

    TXG 1-Year Stock Price Chart
    TXG 1-Year Stock Price Chart

    While consensus focuses on steady 5.4 percent annual revenue growth, the most optimistic analysts were assuming closer to 7.9 percent and US$784.3 million by 2028, so Cathie Wood’s renewed buying may either support that stronger adoption story or expose how differently you and those bullish forecasts view the same risks.

    Explore 4 other fair value estimates on 10x Genomics - why the stock might be worth 34% less than the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Ready For A Different Approach?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.